Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Pharmacokinetic and Pharmacogenetic Analysis of Bosutinib in Japanese Patients with Chronic-Phase Chronic Myeloid Leukemia

Akiko Mita, MD, Maiko Abumiya, PhD, Saori Takahashi, Ms, Yoshihiro Kameoka, MD PhD, Masatomo Miura, PhD, Naoto Takahashi, MD

Blood (2018) 132 (Supplement 1): 4271.

https://doi.org/10.1182/blood-2018-99-111905

Published: 2018

Journal Articles

Lenalidomide and Dexamethasone Therapy in Elderly Patients with Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide

Takahiro Kobayashi, MD, Masatomo Miura, Takenori Niioka, Yuki Fujioka, Maiko Abumiya, Tomoko Yoshioka, Yoshihiro Kameoka, Hiroyoshi Nishikawa, Naoto Takahashi

Blood (2017) 130 (Supplement 1): 3846.

https://doi.org/10.1182/blood.V130.Suppl_1.3846.3846

Published: 2017

Journal Articles

Possibility of Lenalidomide Therapy and Determination of Its Ideal Dose for Patients with Relapsed or Refractory Multiple Myeloma

Seiji Shida, MD, Naoto Takahashi, MD, PhD, FJSIM, Masatomo Miura, PhD, Takenori Niioka, PhD, Morio Matsumoto, MD, Masao Hagihara, MD, Mutsuhito Motegi, MD, PhD, Masaaki Kume, MD, PhD, Jun Kuroki, MD, PhD, Atsushi Kitabayashi, MD, PhD, Yoshiaki Hatano, MD, PhD, Atsushi Watanabe, MD, PhD, Naohito Fujishima, MD, PhD, Yoshihiro Kameoka, MD, PhD, Hiroyuki Tagawa, MD, PhD, Makoto Hirokawa, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2012) 120 (21): 4921.

https://doi.org/10.1182/blood.V120.21.4921.4921

Published: 2012

Journal Articles

CDR3-Independent Expansion of Vδ1 γδ T Lymphocytes and Depletion of Vδ2 T Cells Are Unique Features in Acquired Chronic Pure Red Cell Aplasia,

Michishita Yoshihiro, MD, Makoto Hirokawa, MD, PhD, Naohito Fujishima, MD, PhD, Yukiko Abe, Masumi Fujishima, MD, PhD, Yong-Mei Guo, MD, PhD, Kumi Ubukawa, MD, Liu Jiajia, MD, Tomoko Yoshioka, MD, PhD, Yoshihiro Kameoka, MD, PhD, Hirobumi Saitoh, MD, PhD, Hiroyuki Tagawa, MD, PhD, Naoto Takahashi, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2011) 118 (21): 3429.

https://doi.org/10.1182/blood.V118.21.3429.3429

Published: 2011

Journal Articles

Safety, Feasibility and Efficacy of High Dose Ranimustine (MCNU), Carboplatin, Etoposide, and Cyclophosphamide (MCVC) Therapy Followed by Autologous Stem Cell Transplantation for Malignant Lymphoma.

Yoshihiro Kameoka, MD, PhD, Naoto Takahashi, MD, PhD, Kenichi Ishizawa, MD, PhD, Kazunori Murai, MD, PhD, Yuichi Kato, MD, PhD, Hideyoshi Noji, MD, PhD, Jugo Ito, MD, PhD, Makoto Hirokawa, MD, PhD, Katsusi Tajima, MD, PhD, Tsutomu Shichishima, MD, PhD, Yoji Ishida, MD, PhD, Hideo Harigae, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2010) 116 (21): 4588.

https://doi.org/10.1182/blood.V116.21.4588.4588

Published: 2010

Journal Articles

Dasatinib Cerebrospinal Fluid Concentration and Plasma Pharmacokinetics: Potential for Central Nervous System Prophylaxis In Philadelphia Chromosome-Positive Leukemia

Naoto Takahashi, MD, PhD, Masatomo Miura, PhD, Stuart Scott, PhD, Hirobumi Saitoh, MD, PhD, Mutsuhito Motegi, MD, PhD, Naohito Fujishima, MD, PhD, Yoshihiro Kameoka, MD, PhD, Hiroyuki Tagawa, MD, PhD, Makoto Hirokawa, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2010) 116 (21): 1807.

https://doi.org/10.1182/blood.V116.21.1807.1807

Published: 2010

Journal Articles

The Role of Mir-150 as a Tumor Suppressor In Malignant Lymphoma

Atsushi Watanabe,, MD, Hiroyuki Tagawa, MD, PhD, Kazuaki Teshima, MD, Yoshihiro Kameoka, MD, PhD, Naoto Takahashi, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2010) 116 (21): 465.

https://doi.org/10.1182/blood.V116.21.465.465

Published: 2010

Journal Articles

Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer–cell lymphoma/leukemia

Yasuo Yamanaka, Hiroyuki Tagawa, Naoto Takahashi, Atsushi Watanabe, Yong-Mei Guo, Keiko Iwamoto, Junsuke Yamashita, Hirobumi Saitoh, Yoshihiro Kameoka, Norio Shimizu, Ryo Ichinohasama, Ken-ichi Sawada

Blood (2009) 114 (15): 3265–3275.

https://doi.org/10.1182/blood-2009-06-222794

Published: 2009

Includes: Supplemental data

Journal Articles

MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes

Mika Inomata, Hiroyuki Tagawa, Yong-Mei Guo, Yoshihiro Kameoka, Naoto Takahashi, Kenichi Sawada

Blood (2009) 113 (2): 396–402.

https://doi.org/10.1182/blood-2008-07-163907

Published: 2009

Journal Articles

MicroRNA-17-92 Downregulates Expression of Distinct Targets in Different B-Cell Lymphoma Subtypes

Hiroyuki Tagawa, MD, PhD, Mika Inomata, MD, Yong-Mei Guo, MD, Yoshihiro Kameoka, MD, PhD, Naoto Takahashi, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2008) 112 (11): 5321.

https://doi.org/10.1182/blood.V112.11.5321.5321

Published: 2008

Journal Articles

Low Dose and Standard Dose of Imatinib Therapy for Patients with Chronic Myeloid Leukemia in Akita Prefecture, Japan.

Naoto Takahashi, PhD, Yoshihiro Kameoka, PhD, Hirofumi Saitoh, PhD, Naohito Fujishima, PhD, Makoto Hirokawa, PhD, Kenichi Sawada, PhD

Blood (2007) 110 (11): 4575.

https://doi.org/10.1182/blood.V110.11.4575.4575

Published: 2007

Journal Articles

Array CGH Analysis for Target Genes at 6p21 Amplification Region in Diffuse Large B-Cell Lymphoma.

Yumiko Kasugai, B.S., Hiroyuki Tagawa, M.D., Yoshihiro Kameoka, M.D., Sivasundaram Karnan, Ph.D., Ritsuro Suzuki, M.D., Shinobu Tsuzuki, M.D., Yoshitaka Hosokawa, M.D., Masao Seto, M.D.

Blood (2004) 104 (11): 1116.

https://doi.org/10.1182/blood.V104.11.1116.1116

Published: 2004

Journal Articles

Contig Array CGH at 3p14.2 Points to the FHIT Gene as the Deleted Gene in Diffuse Large B Cell Lymphoma.

Yoshihiro Kameoka, M.D., Hiroyuki Tagawa, M.D., Shinobu Tsuzuki, M.D., Akinobu Ota, B.S., Ritsuro Suzuki, M.D., Masao Seto, M.D.

Blood (2004) 104 (11): 1543.

https://doi.org/10.1182/blood.V104.11.1543.1543

Published: 2004

NARROW

Pharmacokinetic and Pharmacogenetic Analysis of Bosutinib in Japanese Patients with Chronic-Phase Chronic Myeloid Leukemia

Lenalidomide and Dexamethasone Therapy in Elderly Patients with Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide

Possibility of Lenalidomide Therapy and Determination of Its Ideal Dose for Patients with Relapsed or Refractory Multiple Myeloma

CDR3-Independent Expansion of Vδ1 γδ T Lymphocytes and Depletion of Vδ2 T Cells Are Unique Features in Acquired Chronic Pure Red Cell Aplasia,

Safety, Feasibility and Efficacy of High Dose Ranimustine (MCNU), Carboplatin, Etoposide, and Cyclophosphamide (MCVC) Therapy Followed by Autologous Stem Cell Transplantation for Malignant Lymphoma.

Dasatinib Cerebrospinal Fluid Concentration and Plasma Pharmacokinetics: Potential for Central Nervous System Prophylaxis In Philadelphia Chromosome-Positive Leukemia

The Role of Mir-150 as a Tumor Suppressor In Malignant Lymphoma

Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer–cell lymphoma/leukemia

MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes

MicroRNA-17-92 Downregulates Expression of Distinct Targets in Different B-Cell Lymphoma Subtypes

Low Dose and Standard Dose of Imatinib Therapy for Patients with Chronic Myeloid Leukemia in Akita Prefecture, Japan.

Array CGH Analysis for Target Genes at 6p21 Amplification Region in Diffuse Large B-Cell Lymphoma.

Contig Array CGH at 3p14.2 Points to the FHIT Gene as the Deleted Gene in Diffuse Large B Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only